Show simple item record

dc.contributor.authorFrizziero, Melissa
dc.contributor.authorKilgour, Elaine
dc.contributor.authorSimpson, Kathryn
dc.contributor.authorRothwell, Dominic G
dc.contributor.authorMoore, D. A.
dc.contributor.authorFrese, Kristopher K
dc.contributor.authorGalvin, M.
dc.contributor.authorLamarca, Angela
dc.contributor.authorHubner, Richard A
dc.contributor.authorValle, Juan W
dc.contributor.authorMcNamara, Mairéad G
dc.contributor.authorDive, Caroline
dc.date.accessioned2022-02-22T11:44:39Z
dc.date.available2022-02-22T11:44:39Z
dc.date.issued2022en
dc.identifier.citationFrizziero M, Kilgour E, Simpson KL, Rothwell DG, Moore DA, Frese KK, et al. Expanding therapeutic opportunities for Extra-Pulmonary Neuroendocrine Carcinoma. Clinical Cancer Research. American Association for Cancer Research (AACR); 2022. p. clincanres.3058.2021.en
dc.identifier.pmid35091446en
dc.identifier.doi10.1158/1078-0432.Ccr-21-3058en
dc.identifier.urihttp://hdl.handle.net/10541/625063
dc.description.abstractPoorly-Differentiated NeuroEndocrine Carcinomas (PD-NECs) are rare cancers garnering interest as they become more commonly encountered in clinic. This is due to improved diagnostic methods and the increasingly observed phenomenon of 'NE lineage plasticity', whereby non-NeuroEndocrine (non-NE) epithelial cancers transition to aggressive NE phenotypes after targeted treatment. Effective treatment options for patients with PD-NEC is challenging for several reasons. This includes a lack of targetable, recurrent molecular drivers, a paucity of patient-relevant preclinical models to study biology and test novel therapeutics, and the absence of validated biomarkers to guide clinical management. Whilst advances have been made pertaining to molecular subtyping of Small Cell Lung Cancer (SCLC), a PD-NEC of lung origin, Extra-Pulmonary (EP)-PD-NECs remain understudied. This review will address emerging SCLC-like, same-organ non-NE cancer-like and tumour type-agnostic biological vulnerabilities of EP-PD-NECs, with the potential for therapeutic exploitation. The hypotheses surrounding the origin of these cancers and how 'NE lineage plasticity' can be leveraged for therapeutic purposes is discussed. SCLC is herein proposed as a paradigm for supporting progress towards precision medicine in EP-PD-NECs. The aim of this review is to provide a thorough portrait of the current knowledge of EP-PD-NEC biology, with a view to informing new avenues for research and future therapeutic opportunities in these cancers of unmet need.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1078-0432.Ccr-21-3058en
dc.titleExpanding therapeutic opportunities for Extra-Pulmonary Neuroendocrine Carcinomaen
dc.typeArticleen
dc.contributor.departmentCancer Biomarker Centre, Cancer Research UK Manchester Institute. Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute. Department of Oncology, UCL Cancer Centre. Christie Hospital NHS Foundation Trust. Medical Oncology, The Christie Hospital. Medical Oncology, University of Manchester. Cancer Biomarker Centre, Cancer Research UK Manchester Institute caroline.dive@cruk.manchester.ac.uk.en
dc.identifier.journalClinical Cancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record